ClinicalTrials.gg
CompletedNCT05924880TopDoubleUpdated Apr 22, 2025

A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)

A Phase 3 interventional study of durvalumab in Biliary Tract Cancers, sponsored by AstraZeneca. Completed at 19 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-22.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
116
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing durvalumab in Biliary Tract Neoplasms — 5 open to participants now, 11 under way, 2 of them phase 3. durvalumab · Biliary Tract Neoplasms.

Enrollment
5th of 16
116 · median 50
Started
2023
with 3 others
Phase 3
3 of 16
none open now
Registered
11th of 16
by date
Lead sponsor
4 of 16
AstraZeneca

Among the 16 studies testing durvalumab in Biliary Tract Neoplasms, this one is the 5th largest by enrollment, is one of 4 that started in 2023, is one of 3 in phase 3, and was the 11th registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 199 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

5 of the 16 studies testing durvalumab in Biliary Tract Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 140 Biliary Tract Neoplasms studies recruiting now, 80 (57%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing durvalumab in Biliary Tract Neoplasms, or all of them as a file.
02

Study summary

This is a Phase IIIb, open-label, single arm, multicentre study to assess the safety and efficacy of durvalumab in combination with investigator's choice of 3 different gemcitabine-based chemotherapy regimens in participants with aBTC with a WHO/ECOG PS of 0 to 2 at enrolment.

Read the detailed description

The primary objective of the study is to assess the safety of durvalumab combined with gemcitabine-based chemotherapy for participants with advanced BTC who have not previously received systemic therapy for advanced or metastatic BTC with WHO/ECOG PS of 0 to 2.

Eligible participants will received durvalumab in combination with gemcitabine-based chemotherapy(Gemcitabine+Oxalipatin; Gemcitabine+S1, Gemcitabine+Cisplatin) by investigator's choice.

03

Conditions studied

  • Biliary Tract Cancers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be ≥ 18 years at the time of screening.
  2. confirmed, unresectable advanced or BTC including cholangiocarcinoma (intrahepatic or extrahepatic), gallbladder carcinoma.
  3. Participants with previously untreated disease are eligible if presented with unresectable or metastatic BTC at initial diagnosis.
  4. Prior curative intent treatment (surgery and, if given in the setting, chemotherapy and/or radiation) is permitted, with recurrent disease >6 months. This includes participants with residual disease after surgery, who received chemotherapy, chemoembolization, or radiotherapy.
  5. A PS of 0 to 2.
  6. At least one lesion that qualifies as a 1.1 TL at baseline.
  7. Participants with infection (as characterised by positive HBsAg and/or anti-HBcAb with detectable HBV DNA, as per local laboratory standards) must be treated with antiviral therapy, as per institutional practice, to ensure adequate viral suppression (as per local laboratory standards) prior to enrolment. Participants must remain on antiviral therapy for the study duration and for 6 months after the last dose of study intervention. Participants who test positive for anti-HBc with undetectable HBV DNA (as per local laboratory standards) do not require antiviral therapy prior to enrolment. These participants will be tested at every cycle to monitor HBV DNA levels and initiate antiviral therapy if HBV DNA is detected (as per local laboratory standards). HBV DNA detectable participants must initiate and remain on antiviral therapy for the study duration and for 6 months after the last dose of study intervention.
  8. Adequate organ and marrow function, as defined below.

    • ≥ 9 g/dL
    • ≥ 1.5 × 109/L
    • count ≥ 100 × 109/L
    • Serum ≤ 2.0 × ; this will not apply to participants with confirmed Gilbert's syndrome. Any biliary obstruction should be resolved before enrolment.
    • and AST ≤ 2.5 × ULN. For participants with hepatic metastases, ALT and AST ≤ 5 × ULN.
    • Calculated > 50 mL/minute as determined by Cockcroft-Gault (using actual body weight) or 24-hour urine creatinine clearance. For chemotherapy regimens including carboplatin, oxaliplatin, or gemcitabine as monotherapy, the recommended threshold for calculated creatinine clearance is > 40 mL/minute as determined by Cockcroft-Gault (using actual body weight) or 24-hour urine creatinine clearance.
  9. Must have a of at least 12 weeks.
  10. Body weight of > 30 kg.
  11. Male or female.
  12. Negative pregnancy test (serum) for women of .
  13. Female participants must be one year (amenorrhoeic for 12 months without an alternative medical cause), surgically sterile, or using one highly effective form of (a highly effective method of contraception is defined as one that can achieve a failure rate of less than 1% per year when used consistently and correctly). Women of childbearing potential must agree to use one highly effective method of birth control (see Appendix H for a complete list of highly effective birth control methods). They should have been stable on their chosen method of birth control from the time of screening throughout the total duration of the study and the drug (90 days after the last dose of study intervention with durvalumab or 180 days after the last dose of durvalumab and gemcitabine-based therapy).

    • Non-sterilised male partners of a woman of childbearing potential must use a male condom plus spermicide (condom alone in countries where spermicides are not approved) throughout this period. Cessation of birth control after this point should be discussed with a responsible physician. Periodic abstinence, as well as the rhythm and withdrawal methods are not acceptable methods of birth control.
  14. Male participants who intend to be sexually active with a female partner of childbearing potential must be surgically sterile or using an acceptable method of contraception (see Appendix H) from the time of screening throughout the total duration of the study and the drug washout period (90 days after the last dose of study intervention with durvalumab or 180 days after the last dose of durvalumab and gemcitabine-based therapy) to prevent pregnancy in a partner. Male participants must not donate or bank sperm during this same time period.

    • Female partners (of childbearing potential) of male participants must also use a highly effective method of contraception throughout this period.
  15. Participant is capable of giving signed as described in Appendix A, Section A3 which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
  16. Written informed consent from the participant has been obtained prior to any study-related procedures.

Exclusion criteria

Exclusion Criteria:

  1. Ampullary carcinoma.
  2. As judged by the investigator, any evidence of diseases (such as severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diseases, active infection, active ILD/pneumonitis, serious chronic gastrointestinal conditions associated with diarrhoea, psychiatric illness/social situations), history of allogenic organ transplant, which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardise compliance with the protocol.
  3. Active or prior documented or inflammatory disorders including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis], Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc). The following are exceptions to this criterion:

    • Participants with vitiligo or alopecia.
    • Participants with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement.
    • Any chronic skin condition that does not require systemic therapy.
    • Participants without an active disease in the last 5 years may be included but only after consultation with the study physician.
    • Participants with celiac disease controlled by diet alone.
    • Participants with ≥ Grade 2 lymphopenia will be evaluated on a case-by- case basis after consultation with the study physician
  4. History of another primary , except for malignancy treated with curative intent and with no known active disease ≥ 5 years before the first dose of study intervention and of low potential risk for recurrence, basal cell carcinoma of the skin, squamous cell carcinoma of the skin or lentigo maligna that has undergone potentially curative therapy, or adequately treated carcinoma in situ without evidence of disease.
  5. History of .
  6. History of active primary immunodeficiency.
  7. Known to have tested positive for (positive HIV 1/2 antibodies) or active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).
  8. Participants co-infected with (presence of HBsAg and/or anti-HBcAb with detectable HBV DNA, as per local laboratory standards) and (presence of anti-HCV antibodies), or coinfected with HBV and HDV (presence of anti-HDV antibodies).
  9. Persistent toxicities ( Grade > 2) caused by previous anticancer therapy; alopecia and vitiligo are excluded toxicities.

    • Participants with Grade ≥ 2 neuropathy will be evaluated on a case-by-case basis after consultation with the study physician.
    • Participants with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the study physician.
  10. History of previous or current, or spinal cord compression (including asymptomatic and adequately treated disease). Participants with suspected brain metastases at screening should have an MRI (preferred) or CT scan, each preferably with IV contrast of the brain prior to study entry.
  11. Known allergy or to any of the study intervention or any of the study intervention .
  12. Any concurrent chemotherapy, other than the one allowed in the study, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (eg, hormone replacement therapy) is acceptable.
  13. Palliative radiotherapy with a limited field of radiation within 2 weeks of the first dose of study intervention, or radiotherapy with a wide field of radiation or radiotherapy affecting more than 30% of the bone marrow within 4 weeks before the first dose of study intervention. Prior locoregional therapy, such as radioembolization, is allowed as long as done more than 2 weeks prior.
  14. Receipt of within 30 days prior to the first dose of study intervention (see Appendix J). Enroled participants should not receive live vaccine while receiving study intervention and up to 30 days after the last dose of IP.
  15. Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of IP. Minor surgery of isolated lesions for palliative intent is acceptable if performed more than 14 days prior to the first dose of IP.
  16. Prior exposure to immune-mediated therapy including, but not limited to, other , anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies, excluding therapeutic anticancer vaccines.
  17. Current or prior use of medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:

    • Intranasal, inhaled, or topical or local steroid injections (eg, intra-articular injection).
    • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent.
    • Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication).
  18. Receipt of the last dose of anticancer therapy (chemotherapy, targeted therapy, biologic therapy, or mAbs) within 28 days prior to the first dose of study intervention or 5 half-lives of the respective study intervention, whichever is longer.
  19. Participation in another clinical study with a study intervention administered in the last 3 months.
  20. Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study, or during the follow-up period of an interventional study.
  21. Prior randomisation or study intervention in a previous durvalumab clinical study, regardless of study intervention arm assignment.
  22. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  23. Female participants who are pregnant or breastfeeding or male or female participants of who are not willing to use effective from screening to 90 days after the last dose of study intervention with durvalumab or 180 days after the last dose of durvalumab and gemcitabine-based therapy.
  24. Judgement by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    durvalumab in combination with gemcitabine-based chemotherapy

    single-arm

    Drug: durvalumab

Interventions

  • Durvalumab 1500 mg as a 60-minute IV infusion in combination with gemcitabine-based chemotherapy Q3W. Upon completing chemotherapy, or discontinuing chemotherapy due to toxicity, durvalumab 1500 mg IV Q4W alone or in combination with gemcitabine.

    Also known as: IMFINZI

06

What researchers measure

Primary outcomes

  1. The incidence of Possible related adverse events(PRAE) Grade 3 or 4

    The primary endpoint of this study is the incidence of Grade 3/4 PRAEs (CTCAE v5.0) of durvalumab combined with gemcitabine-based chemotherapy within 6 months of starting study intervention regardless of length of infusion. PRAEs are where the investigator answered yes to the question "Do you consider that there is a reasonable possibility that the event may have been caused by the investigational product?".

    Time frame: Within 6 months after the initiation of study intervention.

Secondary outcomes

  1. Overall Survival(OS)

    Overall Survival(OS) is defined as the time from the date of the first dose of study intervention until death due to any cause. The measures of interest are median Overall Survival(OS) and Overall Survival at 12 months(OS12).

    Time frame: From first dose of study intervention until death, up to 67.9% OS maturity or at least 12 months after the last subject enrolled, which occurs first

  2. Objective Response Rate (ORR)

    Objective Response Rate (ORR) is defined as the proportion of participants who achieved a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), assessed by BICR per RECIST Version 1.1.

    Time frame: From first dose of study intervention until disease progression or death (whichever occurs first), up to approximately 3 months after the last subject enrolled

  3. Progression-free Survival (PFS)

    Progression-free Survival (PFS) is defined as the time from randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, assessed by the Investigator per RECIST Version 1.1.

    Time frame: From first dose of study intervention until disease progression or death (whichever occurs first), up to approximately 6 months after the last subject enrolled

  4. Disease Control Rate(DCR)

    Disease Control Rate(DCR) is defined as the percentage of participants who have a best objective response of confirmed CR or PR by Week 24/30 or who have demonstrated SD per RECIST 1.1 for at least 24/30 weeks following the start of treatment. The measure of interest is Disease Control Rate at 24 weeks(DCR24) and Disease Control Rate at 30 weeks(DCR30).

    Time frame: From first dose of study intervention until disease progression or death (whichever occurs first), up to approximately 6 months after the last subject enrolled

  5. Duration of Response(DOR)

    Duration of Response(DOR) is defined as the time from the date of first documented response until the date of documented progression per RECIST 1.1 as assessed by the investigator or death due to any cause.

    Time frame: From first dose of study intervention until disease progression or death (whichever occurs first), up to approximately 6 months after the last subject enrolled

  6. Duration of Treatment(DOT)

    Duration of Treatment(DOT) is defined as time on study intervention.

    Time frame: From first dose of study intervention until last dose or death (whichever occurs first), up to 67.9% OS maturity or at least 12 months after the last subject enrolled, which occurs first

  7. Patient-reported Outcomes(PROs)

    Patient-reported outcome assessment is a general term referring to all outcomes and symptoms that are directly reported by the participant.

    Time frame: From first dose of study intervention until 90 days after last dose or death (whichever occurs first)

  8. Incidence of treatment-emergent adverse events(AEs)

    Incidence of treatment-emergent adverse events(AEs), including possible related adverse events(PRAEs), adverse event of special interests(AESIs), immune-mediated adverse events(imAEs), and serious adverse events(SAEs).

    Time frame: From first dose of study intervention until 90 days after last dose or death (whichever occurs first)

  9. Severity of treatment-emergent adverse events(AEs)

    Severity of treatment-emergent AEs, including possible related adverse events(PRAEs), adverse event of special interests(AESIs), immune-mediated adverse events(imAEs), and serious adverse events(SAEs).

    Time frame: From first dose of study intervention until 90 days after last dose or death (whichever occurs first)

  10. Intervention/treatment of treatment-emergent adverse events(AEs)

    Intervention/treatment of treatment-emergent AEs, including possible related adverse events(PRAEs), adverse event of special interests(AESIs), immune-mediated adverse events(imAEs), and serious adverse events(SAEs).

    Time frame: From first dose of study intervention until 90 days after last dose or death (whichever occurs first)

  11. Outcome of treatment-emergent adverse events(AEs)

    Outcome of treatment-emergent AEs, including possible related adverse events(PRAEs), adverse event of special interests(AESIs), immune-mediated adverse events(imAEs), and serious adverse events(SAEs).

    Time frame: From first dose of study intervention until 90 days after last dose or death (whichever occurs first)

  12. Causality of treatment-emergent adverse events(AEs)

    Causality of treatment-emergent AEs, including possible related adverse events(PRAEs), adverse event of special interests(AESIs), immune-mediated adverse events(imAEs), and serious adverse events(SAEs).

    Time frame: From first dose of study intervention until 90 days after last dose or death (whichever occurs first)

  13. Adverse Events(AEs) resulting in study intervention interruption and discontinuation

    Adverse Events(AEs) resulting in study intervention interruption and discontinuation

    Time frame: From first dose of study intervention until 90 days after last dose or death (whichever occurs first)

07

Study locations

19 sites
  • Research Site
    Beijing, 100142, China
  • Research Site
    Beijing, 100210, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chongqing, 400038, China
  • Research Site
    Fuzhou, 350011, China
  • Research Site
    Guangzhou, 510280, China
  • Research Site
    Harbin, 150049, China
  • Research Site
    Hefei, 230001, China
  • Research Site
    Hefei, 230022, China
  • Research Site
    Jinan, 250117, China
  • Research Site
    Nanchang, 330000, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shenyang, 110001, China
  • Research Site
    Tianjin, 300050, China
  • Research Site
    Tianjin, 300060, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Wuhan, 430071, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Xiamen, 361015, China
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Feb 2025, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2023
First posted
Jun 29, 2023
StartActual
Jul 21, 2023
Primary completionActual
Feb 7, 2025
CompletionActual
Feb 7, 2025
Last update
Apr 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05924880
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 29, 2023
Start date
Jul 21, 2023
Primary completion
Feb 7, 2025
Completion
Feb 7, 2025
Last update
Apr 22, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion